| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 50g |
|
||
| Other Sizes |
|
Purity: ≥98%
Fluorouracil (formerly 5-FU; NSC-19893; NSC19893; 5-Fluorouracil), an analogue of uracil, is an approved anticancer medication acting as a potent DNA/RNA synthesis inhibitor. It specifically inhibits the thymidylate synthase (TS) enzyme in tumor cells, which stops nucleotide synthesis from occurring. Fluorouracil, a heterocyclic aromatic organic compound, is approved for the treatment of several solid tumors, such as cancers of the head and neck, colon, breast, and ovarian.
| Targets |
Thymidylate synthase
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Cell Assay |
Adrucil treatment for seven days in 96-well plates (4000 HT-29 cells/well in RPMI 1640 medium with 10% dialyzed fetal bovine serum) results in growth inhibition measurements; increasing Adrucil concentrations are added after allowing for cell attachment for an overnight period. Cells are washed five times with deionized water, fixed with 10% trichloroacetic acid for 60 minutes at 4 °C, and stained with 0.4% sulforhoda-mine B solution for 15 minutes at room temperature after three rounds of rinsing with phosphate-buffered saline (pH 7.4). Rinsing with 1% glacial acetic acid eliminates unstained sulforhodamine B. After that, dried and dissolved in 10 mM Tris-HCl are the stained cell proteins. Using a detector with a wavelength of 540 nm, the optical density value is determined.
|
|
| Animal Protocol |
|
|
| References |
| Molecular Formula |
C4H3FN2O2
|
|
|---|---|---|
| Molecular Weight |
130.08
|
|
| Exact Mass |
130.02
|
|
| Elemental Analysis |
C, 36.93; H, 2.32; F, 14.61; N, 21.54; O, 24.60
|
|
| CAS # |
51-21-8
|
|
| Related CAS # |
|
|
| Appearance |
Solid powder
|
|
| SMILES |
C1=C(C(=O)NC(=O)N1)F
|
|
| InChi Key |
GHASVSINZRGABV-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
|
|
| Chemical Name |
5-fluoro-1H-pyrimidine-2,4-dione
|
|
| Synonyms |
NSC 19893; 5-FU; Fluorouracil; NSC-19893; NSC19893; 5-Fluorouracil; Trade name: Adrucil among many others.
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (19.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (19.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (19.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (19.22 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2.5 mg/mL (19.22 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: 2.5 mg/mL (19.22 mM) in 5% DMSO + 95% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 7: Saline: 10mg/mL |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.6876 mL | 38.4379 mL | 76.8758 mL | |
| 5 mM | 1.5375 mL | 7.6876 mL | 15.3752 mL | |
| 10 mM | 0.7688 mL | 3.8438 mL | 7.6876 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00082706 | Active Recruiting |
Drug: 5-Fluorouracil (5-FU) Drug: Leucovorin |
Bladder Cancer Urethral Cancer |
M.D. Anderson Cancer Center | April 23, 2003 | Phase 2 |
| NCT03337087 | Active Recruiting |
Drug: Fluorouracil Drug: Rucaparib |
Stage IV Colorectal Cancer AJCC v7 Stage IV Pancreatic Cancer AJCC v6 and v7 |
Academic and Community Cancer Research United |
November 2, 2018 | Phase 1 Phase 2 |
| NCT02059499 | Active Recruiting |
Drug: imiquimod Drug: fluorouracil |
Anal Intraepithelial Neoplasia HIV Infection |
AIDS Malignancy Consortium | December 28, 2015 | Phase 3 |
| NCT04736485 | Active Recruiting |
Drug: perioperative treatment | Gastric Cancer by AJCC V8 Stage Resectable Carcinoma |
Centre Francois Baclesse | June 28, 2021 | Phase 2 |
| NCT05669521 | Active Recruiting |
Drug: TK-112690 Drug: Placebo |
Mucositis | Tosk, Inc. | June 15, 2022 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA